No evidence of association between psychological distress and pain relief in patients with bone metastases from castration‐resistant prostate cancer treated with 223Radium-Reference-Cited by-同舟云学术

No evidence of association between psychological distress and pain relief in patients with bone metastases from castration‐resistant prostate cancer treated with 223Radium

Published:2019-05-31 Issue:5 Volume:28 Page:
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

De Vincentis Giuseppe¹,Frantellizzi Viviana¹²^ORCID,Follacchio Giulia Anna¹,Farcomeni Alessio³,Pani Arianna⁴,Samaritani Riccardo⁵,Schinzari Giovanni⁶,Santini Daniele⁷,Cortesi Enrico¹

Affiliation:

1. Department of Radiological Sciences, Oncology and Anatomical Pathology Sapienza University of Rome Rome Italy

2. PhD Program: Angio‐Cardio‐Thoracic Pathophisiology and Imaging "Sapienza" University of Rome Rome Italy

3. Department of Public Health and Infectious Diseases Sapienza University of Rome Rome Italy

4. Postgraduate School of Clinical Pharmacology University of Milan “La Statale” Milan Italy

5. Oncology Unit Regina Margherita Hospital Rome Italy

6. Institute of Internal Medicine, Clinical Oncology Unit Catholic University of Sacred Heart Rome Italy

7. Medical Oncology Department Campus Bio‐Medico University Rome Italy

Publisher

Wiley

Subject

Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.13112

Reference36 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

2. Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

3. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

5. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the relationship between clinician-preferred ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer;2024-06-03

2. Metastatic castration resistant prostate cancer patients’ experience with Radium-223 treatment in Japan;Future Oncology;2024-01-26

4. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223;Prostate Cancer and Prostatic Diseases;2021-08-26

5. Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study;International Journal of Radiation Biology;2020-11-03